Literature DB >> 22512623

Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori.

A Cosme1, M Montes, M Martos, I Gil, U Mendarte, Y Salicio, L Piñeiro, M T Recasens, B Ibarra, C Sarasqueta, L Bujanda.   

Abstract

The rate of eradication of Helicobacter pylori with standard triple therapy using omeprazole, amoxicillin and clarithromycin (OAC) is unacceptable in populations with high rates of clarithromycin resistance (15-20%). The aim of this study was to compare the efficacy of 10-day OAC therapy as the first-line treatment in patients diagnosed by culture with antimicrobial susceptibility or diagnosed by a (13) C-labelled urea breath test (UBT) without antimicrobial susceptibility in an area where the clarithromycin resistance rate was 15-20%. This was a retrospective cohort study of 266 patients, recruited consecutively throughout 2008. A total of 247 H. pylori-infected patients received antibiotic therapy (221 received the 10-day OAC therapy and 26 received other regimens) of which 134 patients were diagnosed by culture of gastric samples followed by antimicrobial susceptibility testing and 113 were diagnosed by UBT. In all patients, the eradication of H. pylori was checked by UBT. The cost of eradication by 10-day OAC treatment was assessed in each patient. The success rate of 10-day OAC therapy in patients diagnosed by culture and by UBT was 88% (103/117) and 49% (51/104), respectively (p <0.0005). The treatment was also more cost-effective in the former of these two groups (€571 versus €666). To perform culture and antimicrobial susceptibility of the H. pylori isolates was a more successful and cost effective strategy than empirical 10-day OAC treatment in populations with high rates of resistance to clarithromycin.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22512623     DOI: 10.1111/j.1469-0691.2012.03844.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  16 in total

1.  Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.

Authors:  Jason Y Park; Kerry B Dunbar; Midori Mitui; Christina A Arnold; Dora M Lam-Himlin; Mark A Valasek; Irene Thung; Chinemerem Okwara; Elizabeth Coss; Byron Cryer; Christopher D Doern
Journal:  Dig Dis Sci       Date:  2016-02-29       Impact factor: 3.199

Review 2.  Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection.

Authors:  Ignasi Puig; Sheila López-Góngora; Xavier Calvet; Albert Villoria; Mireia Baylina; Jordi Sanchez-Delgado; David Suarez; Victor García-Hernando; Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2015-12-16       Impact factor: 4.409

Review 3.  Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance.

Authors:  Sinéad M Smith; Colm O'Morain; Deirdre McNamara
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 4.  Approach to Helicobacter pylori infection in geriatric population.

Authors:  Sevdenur Cizginer; Zehra Ordulu; Abdurrahman Kadayifci
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

5.  Use of the Optum Labs Data Warehouse to assess test ordering patterns for diagnosis of Helicobacter pylori infection in the United States.

Authors:  Elitza S Theel; Ryan D Johnson; Elizabeth Plumhoff; Curtis A Hanson
Journal:  J Clin Microbiol       Date:  2015-01-21       Impact factor: 5.948

6.  Helicobacter pylori Mutations Detected by Next-Generation Sequencing in Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Specimens Are Associated with Treatment Failure.

Authors:  Behtash G Nezami; Mehul Jani; David Alouani; Daniel D Rhoads; Navid Sadri
Journal:  J Clin Microbiol       Date:  2019-06-25       Impact factor: 5.948

Review 7.  Culture-guided treatment approach for Helicobacter pylori infection: review of the literature.

Authors:  Giovanni Cammarota; Gianluca Ianiro; Stefano Bibbò; Teresa Antonella Di Rienzo; Luca Masucci; Maurizio Sanguinetti; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 8.  Helicobacter pylori therapy: a paradigm shift.

Authors:  David Y Graham; Maria Pina Dore
Journal:  Expert Rev Anti Infect Ther       Date:  2016-05-03       Impact factor: 5.091

Review 9.  Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review.

Authors:  Pedro Cortés; Alfred D Nelson; Yan Bi; Fernando F Stancampiano; Loren P Murray; George G A Pujalte; Victoria Gomez; Dana M Harris
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

10.  Changes in Antibiotic Susceptibility of Helicobacter pylori in the Course of Eight Years in the Zaanstreek Region in The Netherlands.

Authors:  R J L F Loffeld; B F M Werdmuller
Journal:  Gastroenterol Res Pract       Date:  2013-03-12       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.